GlassScriptPhysician profile
Rabindra Sagunarthy
NPI 1184822959
$10,292.80
in general payments reported to CMS, 2019-2025
31 companies · $811 in 2025
The $811 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,373 · 2020: $817 · 2021: $1,732 · 2022: $1,733 · 2023: $2,185 · 2024: $1,642 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,637.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,181.91 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $960.39 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $928.86 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $785.63 | 2021-2025 | Teflaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $745.16 | 2019-2025 | Xifaxan |
| Pfizer INC. | $737.49 | 2019-2025 | |
| Gilead Sciences, INC. | $736.51 | 2021-2025 | Veklury |
| Astrazeneca Pharmaceuticals LP | $513.79 | 2019-2025 | Farxiga, Fasenra, Wainua |
| Merck Sharp & Dohme LLC | $468.67 | 2019-2025 | Zerbaxa, Dificid, Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $386.94 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $384.40 | 2022-2024 | Givlaari |
| Paratek Pharmaceuticals, INC. | $368.86 | 2019-2024 | Nuzyra |
| Electromed, INC. | $312.65 | 2019-2024 | Smartvest |
| Boston Scientific Corporation | $300.08 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $279.02 | 2019-2024 | Eliquis, Camzyos |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $163.26 | 2021-2025 | Ultomiris |
| Allergan, INC. | $135.59 | 2019-2020 | |
| Melinta Therapeutics, LLC | $131.03 | 2020-2022 | |
| Scpharmaceuticals INC. | $117.31 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $115.17 | 2019 | |
| Novo Nordisk INC | $95.36 | 2020 | |
| Philips North America LLC | $88.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.34 | 2021 | |
| Inari Medical, INC. | $64.98 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Straumann USA LLC | $52.34 | 2025 | |
| Abbott Laboratories | $45.98 | 2024 | Freestyle Libre 3 |
| Kestra Medical Technology Services, INC. | $38.29 | 2023-2024 | Assure Wcd |
| Masimo Corporation | $27.57 | 2021 | |
| Tactile Systems Technology INC | $20.84 | 2019 | |
| Amgen INC. | $16.42 | 2019 | |
| Cmp Pharma, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabindra Sagunarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.